This content is from: Patents

Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS

The Federal Circuit has ruled that Sandoz did not forfeit its preemption defence and the BPCIA preempts state law remedies in its biosimilars dispute with Amgen. The decision makes clear that brand biologic companies have no remedies available against a biosimilar applicant who is refusing to engage in the patent dance

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial

Related